Can­cer vax biotech Amal grabs $10M round; Glob­al Blood Ther­a­peu­tics eyes PRV with new FDA des­ig­na­tion

⇨ Gene­va-based Amal Ther­a­peu­tics has picked up about $10 mil­lion in Se­ries B mon­ey for its work on pep­tide-based can­cer vac­cines. Boehringer In­gel­heim Ven­ture Fund, Bio­Med­Part­ners and Helsinn In­vest­ment Fund in­vest­ed along­side VI Part­ners, High-Tech Grün­der­fonds and Schroder Ad­veq.

⇨ Glob­al Blood Ther­a­peu­tics $GBT picked up a rare pe­di­atric dis­ease des­ig­na­tion for GBT440, putting it in line for a pos­si­ble pri­or­i­ty re­view vouch­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER